Inventiva (NASDAQ:IVA) Trading 1.3% Higher – What’s Next?

Inventiva S.A. (NASDAQ:IVA) rose 1.3% during mid-day trading on Monday . The stock traded as high as $3.24 and last traded at $3.15. Approximately 7,314 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 63,046 shares. The stock had previously closed at $3.11.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Guggenheim reduced their price target on Inventiva from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, April 4th. TD Cowen started coverage on Inventiva in a research note on Friday, February 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Inventiva in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Inventiva has an average rating of “Moderate Buy” and a consensus price target of $10.40.

Inventiva Trading Up 1.3%

The company has a 50-day simple moving average of $3.27 and a two-hundred day simple moving average of $2.79.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,715 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.